Season 2024
In this episode, we learn about endocrine-disrupting chemicals known as perfluoroalkyl and polyfluoroalkyl substances (PFAS), which break down so slowly that they have been called “forever chemicals.…
Published on 1 year, 8 months ago
Season 2023
According to the National Institutes of Health, more than two in five adults have obesity in the United States, and nearly one in three is overweight. To equip health care practitioners with the reso…
Published on 1 year, 8 months ago
Season 2023
We all know that sleep is important, but sometimes we just don’t get enough. We also know the normal side effects from lack of sleep, but are there other, metabolic, and neuronendocrine effects from …
Published on 1 year, 9 months ago
Season 2023
Today’s topic is type 1 diabetes. What are some of the biggest challenges facing us today when it comes to diagnosing and treating type 1 diabetes, and how can we meet those challenges? Host Aaron Lo…
Published on 1 year, 10 months ago
Season 2023
We know that illicit use of anabolic-androgenic steroids is dangerous, but cessation comes with its own challenges. Today we’re talking about a study presented at ENDO 2023 titled, “Self-Administrati…
Published on 1 year, 10 months ago
Season 2023
We look at a study, presented at ENDO 2023, about the endocrine-disrupting chemicals known as phthalates, or plasticizers, and their effects on fetal and neonatal endocrine puberty. Host Aaron Lohr t…
Published on 1 year, 10 months ago
Season 2023
Published on 1 year, 11 months ago
Season 2023
From ENDO 2023, host Aaron Lohr talks with Jayalakshmi Udayasankar, MD, from the Palo Alto Medical Foundation, about her team’s research presented at the meeting, titled, “Tingling Over Cheek: An Aty…
Published on 1 year, 11 months ago
Season 2023
In another dispatch from ENDO 2023, host Aaron Lohr talks with Max Petersen, MD, PhD, from Washington University in St. Louis, about his team’s research presented at the meeting. Their presentation w…
Published on 2 years ago
Season 2023
Host Aaron Lohr talks with two researchers at ENDO 2023, Kyle Horlen, DVM, and Joshua Myers, both from Rani Therapeutics, about two presentations they made about an oral treatment of teriparatide for…
Published on 2 years ago
If you like Podbriefly.com, please consider donating to support the ongoing development.
Donate